The article highlights key developments in the pharmaceutical industry, including GSK's $12 billion licensing deal with Hengrui Pharma, Takeda's revenue decline due to Vyvanse generic erosion, Celltrion's $504 million U.S. plant acquisition, and other deals involving Madrigal, Instil, and multiple biotech firms.

The global Doxepin Hydrochloride for Injection Market is projected to grow from USD 62.3 million in 2024 to USD 192.4 million by 2034, driven by rising mental health disorders, hospital-based psychiatric care, and off-label use in insomnia treatment. Key players include Pfizer, Mylan, Hikma Pharmaceuticals, and Teva Pharmaceuticals, with challenges including TCA side effects and regulatory scrutiny.

A comprehensive market analysis report from Worldwide Market Reports provides insights into the Actinic Keratosis Drugs Market, covering global regions including the U.S., U.K., South Korea, and Japan. The report analyzes market dynamics, innovation cycles, and business strategies, offering data-backed insights for executives and investors. It segments the market by product types, applications, and geographic regions, while highlighting featured companies and addressing key questions about market growth and competitive positioning.

The Active Pharmaceutical Ingredients Market is projected to grow from USD 268.05 billion in 2025 to USD 424.83 billion by 2032, with a CAGR of 6.8%. The report covers market dynamics, competitive landscape, and segmentation by product type, application, and geography, highlighting key players like Teva, Pfizer, and Dr. Reddy's.

HTF MI released a comprehensive market study projecting the global Onychomycosis market will grow at a 7.2% CAGR from 2025 to 2032, expanding from USD 4.2 Billion to USD 7.5 Billion. The report highlights key players like Pfizer, Bausch Health, Novartis, and Moberg Pharma, and covers market segments by treatment type, application, and regional trends.